Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
10/26/2022 -- Results Q3 2022 -- 1.84 --
10/26/2022 08:00 EST Earnings Call Q3 2022 -- -- --
07/27/2022 08:00 EST Earnings Call Q2 2022 -- -- --
07/27/2022 -- Results Q2 2022 1.93 1.80 7.27%
04/29/2022 -- Results Q1 2022 1.96 1.89 3.48%
04/29/2022 08:00 EST Earnings Call Q1 2022 -- -- --
02/04/2022 -- Results Q4 2021 1.83 1.80 1.66%
02/04/2022 08:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 10/26/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 07/27/2022
Beat/Miss Upgrade
Return Since -4.81%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
URL https://www.bms.com
Investor Relations URL https://www.bms.com/investors.html
HQ State/Province New York
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Value
Next Earnings Release Oct. 26, 2022
Last Earnings Release Jul. 27, 2022
Next Ex-Dividend Date Oct. 06, 2022
Last Ex-Dividend Date Jun. 30, 2022

Dividends

Dividend Per Share (TTM) 2.11
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 2.017
Yield to Sector 1.606
Yield to Industry 0.8014
Last Dividend Amt. 0.54
Dividend Frequency Quarterly
Last Ex-Dividend Date Jun. 30, 2022
Yield (TTM) 2.96%
Forward Yield 3.03%
Payout Ratio 68.37%
Cash Payout Ratio 31.68%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) Yes

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
19.24%
-13.50%
7.72%
-12.91%
27.86%
0.39%
2.89%
16.88%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-19.50%
3.97%
-7.55%
22.25%
15.17%
27.62%
-2.00%
0.87%
6.12%
1.16%
15.32%
24.40%
-5.14%
16.21%
10.85%
11.45%
-1.28%
25.37%
-10.37%
17.83%
40.45%
16.15%
31.06%
66.08%
20.71%
-3.72%
15.23%
-1.33%
40.20%
22.42%
-7.07%
1.86%
18.24%
As of October 04, 2022.

Profile

Edit
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
URL https://www.bms.com
Investor Relations URL https://www.bms.com/investors.html
HQ State/Province New York
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Value
Next Earnings Release Oct. 26, 2022
Last Earnings Release Jul. 27, 2022
Next Ex-Dividend Date Oct. 06, 2022
Last Ex-Dividend Date Jun. 30, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
VGHCX 1.526B USD 3.36%
HDV 359.02M USD 3.10%
VHT 487.25M USD 2.62%
OIEQX 1.143B USD 2.42%
VPMCX 921.67M USD 1.54%
CMLFX 1.192B USD 1.45%
VDADX 912.13M USD 1.24%
VIG 912.13M USD 1.24%
VYM 609.73M USD 1.05%
IWD 437.40M USD 0.91%
VIVAX 1.256B USD 0.87%
VTV 1.256B USD 0.87%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter BMY Tweets